Vulvar and Vaginal Atrophy (VVA) Therapy Market Outlook:
Vulvar and Vaginal Atrophy (VVA) Therapy Market size was valued at USD 2.9 billion in 2025 and is likely to cross USD 8.01 billion by 2035, registering more than 10.7% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of vulvar and vaginal atrophy therapy is assessed at USD 3.18 billion.
The growth of the market can be attributed to the rising number of cases related to the hypoestrogenism condition, known as genitourinary syndrome of menopause (also known as vulvovaginal atrophy or urogenital trophy), among women. For instance, the menopausal genitourinary syndrome affects approximately 30% to 75% of postmenopausal women and can significantly impair health, sexual function, and quality of life.
Global vulvar and vaginal atrophy (VVA) therapy market trends such as rising awareness about VVA therapies among the female population, the vulvar and vaginal atrophy therapy market size is expected to expand notably during the forecast year. According to the National Institute of Health, approximately 1.3 million women in the United States enter menopause each year. The age of menopause begins mostly between 51 and 52 years of age. However, approximately 5% of women worldwide experience early menopause between the ages of 40 and 45, and 1% experience premature menopause, i.e., before the age of 40, due to sex chromosomal abnormalities, resulting in permanent ovarian failure. Hence, all these factors are expected to hike the market growth over the forecast period.
